Investigating new approaches to support brain recovery after stroke.
For millions living with stroke disability, current options are limited. At Neuro-Innovators, we’re investigating whether combining FDA-approved medications in new ways could support the brain’s natural recovery processes.
We are a clinical-stage pharmaceutical company developing NIV-001, an investigational combination therapy aimed at enhancing neuroplasticity—the brain’s capacity to form new connections and repair—in people living with chronic motor disabilities due to stroke.
While NIV-001 is our lead program, our broader approach explores how targeted combination therapies may unlock recovery across neurological conditions.
Rigorous research with compassionate care, focusing on helping stroke survivors reclaim independence.
Repurposing FDA-approved drugs in novel ways to accelerate research timelines while reducing development risk.
Every decision begins with: How does this help people waiting for better treatment options?
Our initial clinical research is conducted in collaboration with Spaulding Rehabilitation Hospital, a member of Mass General Brigham and a nationally ranked leader in physical medicine and rehabilitation. A Phase 1 clinical trial is currently underway at Spaulding, led by Drs. Paolo Bonato and Qing Mei Wang. The trial is registered on ClinicalTrials.gov as NCT07588932.